Genelux

Genelux EPS

The Earnings per Share (EPS) of Genelux (GNLX) as of Oct 15, 2026 is -0.86 USD. In the previous year, Earnings per Share (EPS) was -0.95 USD — a change of -8.96% (higher).

EPS

-0.86USD

YoY

-8.96%

Last updated:

Earnings per Share (EPS) of Genelux is 2025 -0.86 USD. Earnings per Share (EPS) of Genelux was 2024 -0.95 USD. It decreases by -8.96% higher compared to the previous year.

The Genelux EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2023
-1.06 USD
Jan 1, 2024
-0.95 USD
Jan 1, 2025
-0.86 USD
Jan 1, 2026 (e)
-0.82 USD
Jan 1, 2027 (e)
-0.75 USD
Jan 1, 2028 (e)
-0.06 USD
Jan 1, 2029 (e)
1.21 USD
Jan 1, 2030 (e)
3.41 USD
The Genelux EPS history
YEAREPSYoY
est3.41USD+181.45%
est1.21USD-1,974.72%
est-0.06USD-91.41%
est-0.75USD-7.77%
est-0.82USD-5.74%
-0.86USD-8.96%
-0.95USD-10.09%
-1.06USD+398.09%
-0.21USD-62.72%
-0.57USD-9.51%
-0.63USD+142.97%
-0.26USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genelux Stock analysis

What does Genelux do? Genelux Corp, trading under the ticker GNLX, is a biotechnology company based in Westlake Village, California, operating within the Health Care sector. The company has 25 employees and completed its initial public offering on January 26, 2023. Genelux focuses on developing oncolytic viral immunotherapies for solid tumor cancers. Its lead product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a modified vaccinia virus (VACV), a stable DNA virus with significant engineering potential. The company is currently advancing Olvi-Vec through Phase II clinical trials for platinum-resistant or refractory ovarian cancer (PRROC). Additionally, Genelux is developing a platform called Virus and Vaccine (Neoantigen)-Enhanced Adoptive Cell Therapy (V2ACT), which aims to enhance cancer neoantigen-specific T cell activity within tumors. The company also has an animal health product candidate, V-VET1, a genetically characterized, veterinary-grade oncolytic vaccinia virus that is a naturally attenuated isolate. Genelux's website is https://genelux.com/ and it is registered with the ISIN US36870H1032. The company's operations and product development are centered on innovative viral-based therapies for both human and animal health applications. Genelux is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genelux stock

Earnings per Share (EPS) of Genelux is -0.86 USD in 2025.

Earnings per Share (EPS) of Genelux changed from -0.95 USD to -0.86 USD, representing a -8.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Genelux since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Genelux

All Key Metrics — Genelux